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Abstract
Objective: Little is known about the association between free IGF-I levels and bone mineral density
(BMD).
Design: A cross-sectional study of 218 healthy subjects (103 men, 115 women, age 55–80 years) was
carried out.
Methods: Fasting serum free IGF-I, total IGF-I, estradiol and sex hormone-binding globulin (SHBG)
levels were measured. The ratio of estradiol to SHBG was used as an index of free estradiol. BMD
measurements were performed by dual-energy X-ray absorptiometry of the lumbar spine and the
proximal femur.
Results: In multivariate analyses with BMD of the lumbar spine as the dependent variable and serum
free IGF-I, age, body mass index (BMI) and the free estradiol index as independent variables, the free
IGF-I was positively related to the BMD of the lumbar spine in men (P = 0.02) but not in women. When
the same analyses for the lumbar BMD were performed with total serum IGF-I the association was also
only statistically significant in men (P = 0.05). In multivariate analyses with the trochanter BMD as
the dependent variable and serum free IGF-I, total IGF-I, age, BMI and the free estradiol index as
independent variables, the associations between (free and total) IGF-I and the trochanter BMD in men
was of borderline significance.
Conclusions: In elderly men free and total IGF-I were positively related to lumbar BMD, while (free and
total) IGF-I was borderline positively related to trochanter BMD. As these relationships were not
observed in elderly women, we suggest a weak gender-specific anabolic effect of IGF-I on BMD on
trabecular bone.
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Introduction
Insulin-like growth factor-I (IGF-I) and its specific
insulin-like growth factor-binding proteins (IGFBPs)
are postulated to play a key role in bone metabolism
(1). It is generally agreed that IGF-I has anabolic effects
on bone cells (2). It has been shown to be an important
regulator of bone remodeling and growth (3) and has
been found to stimulate collagen synthesis in bone,
resulting in increased matrix production (4). Bone cells
synthesize IGF-I and all of the six IGFBPs (1) and
observations in osteoblast-like cell lines have suggested
that skeletal concentration of IGF-I is a reflection of its
local synthesis by osteoblasts (3).
Recently a method was developed to measure free
serum IGF-I (5, 6). Free IGF-I, analogous to free sex and
adrenal steroids and thyroid hormones, is likely to be a
major biologically active hormonal form of IGF-I (7).
Estrogens have a protective effect on bone mass and
slow bone loss during aging (8). Moreover, it has been
suggested that the estrogen status in women has a
complex effect on serum concentrations of IGF-I and
therefore has to be taken into account when evaluating
levels of serum IGF-I (9).
In order to gain more insight into the relationships
between systemic IGF-I, estrogens and bone mineral
density (BMD) in the elderly, we measured serum free
and total IGF-I levels, estrogens and BMD in 218
healthy elderly subjects.
Materials and methods
Study population
The population for the present study included 218
subjects aged 55 to 80 years, who had completed the
baseline visit of the Rotterdam Study not more than 6
months earlier. The Rotterdam Study is a population-
based prospective cohort study of determinants of
chronic disabling diseases in the elderly and has been
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described elsewhere (10). Briefly, all 10 275 inhabitants
of a suburb of Rotterdam, aged 55 years and over, were
invited to participate. From the 9161 independently
living persons 77% participated in the interview and
71% also had extensive examinations including bone
density measurements.
The 218 people who took part in the present study
were randomly selected from the 7983 participants
of the Rotterdam Study after exclusion of subjects
with acute psychiatric disease or diabetes. Compared
with the other participants of the Rotterdam Study
without known diabetes mellitus, there were no
differences in age and gender distribution, mean blood
pressure, use of antihypertensive drugs, echocardio-
graphic evidence of atherosclerotic plaques in the
carotid arteries and electrocardiographic abnormalities.
Only four women in this study population were on
hormone replacement therapy. These four women were
excluded from analysis. Informed consent was obtained
from all subjects and the study was approved by the
medical ethics committee of Erasmus University Medical
School.
Measurements
Biochemical measurement Participants were exam-
ined in the morning after an overnight fast. Fasting
blood samples were taken by venipuncture between
0800 and 0900 h and allowed to coagulate for 30 min.
Subsequently serum was separated by centrifugation
and quickly frozen in liquid nitrogen. Free IGF-I was
measured with a commercially available two-site IRMA
(Diagnostic System Laboratories Inc., Webster, TX, USA;
intra-assay and inter-assay coefficients of variation (CV)
were 10.3 and 10.7% respectively) (5, 6).
The free IGF-I assay needs no initial sample extraction
as part of the standard procedure to measure IGF-I.
Samples are added directly to tubes containing a dense
coating of high-affinity free IGF-I antibody, incubated
for 2 h at room temperature, washed, incubated with
125I-labeled antibody directed to a second epitope,
washed and counted. There was no cross-reactivity
with IGF-II and no residual IGFBP-1 or IGFBP-3 was
detected after the first wash. It is likely that the free IGF-I
fraction measured with the free IGF-I assay is a
combination of the true free and the fraction of IGF-I
which can be readily dissociated from IGFBPs under the
specific assay conditions (5). Total IGF-I was determined
by a commercially available RIA (Medgenix Diagnostics,
Brussels, Belgium; intra-assay and inter-assay CV 6.1
and 9.9%) after an acidification/neutralization step.
The purpose of this step was to convert the different
forms of IGF-I present into free IGF-I.
Estradiol was assayed with an RIA (Diagnostic Prod-
ucts Corporation, Los Angeles, CA, USA; intra-assay and
inter-assay CV 7.0 and 8.1%). Sex hormone-binding
globulin (SHBG) was assayed with a commercially
available IRMA (Diagnostic Products Corporation;
intra-assay and inter-assay CV 3.6 and 6.9%). The
ratio of estradiol to SHBG was used as an index of free
estradiol (11). Height and weight were measured
wearing indoor clothes and without shoes. Body mass
index (BMI) was defined as weight divided by the square
of height (kg/m2).
Measurement of BMD BMD measurements were
performed by dual-energy X-ray absorptiometry,
using a Lunar DPX-L densitometer (Lunar Radiation
Corporation, Madison, WI, USA). Standard positioning
was used with anterior–posterior scans of the lumbar
spine and the right proximal femur. If there was a
history of hip fracture or prothesis implantation, the left
femur was scanned. Using standard software the
vertebrae L2 to L4, and at the proximal femur, the
femoral neck, Ward’s triangle and the greater trochan-
ter were analyzed. Quality assurance included calibra-
tion with the standard of the machine and was
performed routinely every morning. The in vivo CV for
BMD measurements was 0.9% in the lumbar spine,
3.2% in the femoral neck, 3.1% in the Ward’s triangle,
and 2.5% in the greater trochanter.
Statistical analysis Pearson’s correlation coefficients
were calculated to assess the associations between IGF-I
and BMD, after adjustment for age, and other con-
founders when appropriate. Analyses in which the
values were logarithmically transformed yielded results
similar to those with untransformed data. Because
interpretation of results from logarithmically trans-
formed data is more difficult, the non-transformed
results are presented. Linear regression analysis was
used to calculate the statistical significance of differ-
ences in general characteristics between men and
women, as well as the associations between IGF-I and
BMD, after adjustment for age, and other confounders
when appropriate. A two-sided P value of <0.05 was
considered significant. All statistical analyses were
performed with a Stata statistical package (Computing
Resource Center, Santa Monica, CA, USA).
Results
In Table 1 general characteristics of the study popula-
tion are presented. Men were slightly older than women.
Mean (free and total) IGF-I levels did not differ between
the sexes. BMD was (age-adjusted) higher in men than
in women at all four measured sites. Mean free estradiol
index was significantly higher in men than in women.
Serum free IGF-I was positively associated with total
IGF-I (r ¼ 0.35, P < 0.001). Serum total IGF-I decreased
with age in women, while this relationship just missed
significance in men (Table 2). Free IGF-I was not related
to age in either sex (Table 2). Free IGF-I was inversely
related to BMI in men, but this relationship was lost
after adjustment for age. Total IGF-I was not signifi-
cantly related to BMI in either sex (Table 2).
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No (age-adjusted) relationships were present between
serum free IGF-I and the free estradiol index in either sex
(men: r ¼ 0.13, P ¼ 0.21; women: r ¼ 0.16, P ¼ 0.10).
Total serum IGF-I was (age-adjusted) positively related
to free estradiol index in men and women (men:
r ¼ 0.24, P ¼ 0.02; women: r ¼ 0.26, P ¼ 0.008).
BMD at all four measured sites was (age-adjusted)
significantly related to BMI (lumbar: r ¼ 0.33; trochan-
ter: r ¼ 0.36; femoral neck: r ¼ 0.38; Ward’s triangle:
r ¼ 0.36; P in all four sites <0.001). Similar relation-
ships between BMD and BMI were observed when men
and women were analyzed separately (data not shown).
No relationships were observed in the total study
population between free or total IGF-I, and the BMD of
the lumbar spine, femoral neck, Ward’s triangle and the
greater trochanter respectively, without further adjust-
ments. To give an impression of the distribution of the
data the relationships between (total and free) IGF-I and
the lumbar spine and between (total and free) IGF-I
and the greater trochanter are showed in Figs 1 and 2.
Only in men were free IGF-I and total IGF-I significantly
associated with BMD of the lumbar spine after adjust-
ment for BMI and age (Table 3). The relationship
between both free IGF-I and total IGF-I respectively, and
trochanter BMD in men reached borderline significance
after the same adjustments. In multivariate analyses
with BMD of the lumbar spine as the dependent variable
and free IGF-I, age, BMI and the free estradiol index
as independent variables, the association between free
IGF-I and the BMD of the lumbar spine in men remained
statistically significant (r ¼ 0.24, P ¼ 0.02). When the
same analyses for the lumbar BMD were performed with
total IGF-I rather than free IGF-I, the association was
statistically significant in men (r ¼ 0.21, P ¼ 0.05). In
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Table 1 Distribution of variables by sex (mean 6 S.E.M.).
Men Women
(n ¼ 103) (n ¼ 111) P
Age (years) 67:6 6 0:6 65:9 6 0:6 0.05
BMI (kg/m2) 26:4 6 0:3 26:6 6 0:4 0.70**
Total IGF-I* (nmol/l) 19:3 6 0:83 17:9 6 0:70 0.11**
Free IGF-I* (nmol/l) 0:088 6 0:005 0:095 6 0:005 0.22**
SHBG* (nmol/l) 50:9 6 2:0 60:2 6 2:7 0.006**
Estradiol* (pmol/l) 106:4 6 17:2 82:1 6 4:8 0.10**
Free estradiol index* (pmol/nmol) 2:26 6 0:25 1:65 6 0:13 0.009**
BMD (g/cm2)
Lumbar spine 1:19 6 0:02 1:03 6 0:02 <0.001**
Femoral neck 0:87 6 0:01 0:81 6 0:01 0.003**
Ward’s triangle 0:71 6 0:02 0:73 6 0:01 0.027**
Greater trochanter 0:83 6 0:01 0:73 6 0:01 <0.001**
* Fasting values.
** Difference between men and women, adjusted for age.
Table 2 Association between fasting total and free IGF-I levels
and age and BMI.
Variable* Sex r P
Total IGF-I
Age Men ¹0.17 0.09
Women ¹0.28 0.003
Free IGF-I
Age Men 0.14 0.15
Women 0.10 0.27
BMI
Total IGF-I Men ¹0.003 0.97
Women 0.09 0.35
Free IGF-I Men ¹0.20 0.05
Women ¹0.004 0.94
* Dependent variable is underlined.
Table 3 Associations between BMD at various sites and fasting total
and free IGF-I levels in men and women*.
Men Women
Variable* r P r P
Lumbar spine
Total IGF-I 0.22 0.03 ¹0.10 0.35
Free IGF-I 0.24 0.02 ¹0.009 0.93
Femoral neck
Total IGF-I 0.11 0.29 ¹0.12 0.27
Free IGF-I 0.09 0.36 ¹0.05 0.65
Ward’s triangle
Total IGF-I 0.15 0.15 ¹0.06 0.56
Free IGF-I 0.15 0.14 ¹0.04 0.72
Greater trochanter
Total IGF-I 0.19 0.06 0.007 0.94
Free IGF-I 0.18 0.08 0.02 0.89
* Adjusted for age and BMI.
** Dependent variable is underlined.
analyses with the trochanter BMD as the dependent
variable and free IGF-I, age, BMI and the free estradiol
index as independent variables, the association between
free IGF-I and the trochanter BMD in men just missed
significance (r ¼ 0.19, P ¼ 0.06). When the same adjust-
ments were performed for the relationship between the
trochanter BMD and total IGF-I, this association
remained of borderline statistical significance (r ¼ 0.19,
P ¼ 0.06).
Discussion
In this population-derived sample of elderly subjects
both free and total IGF-I were weakly positively related
to BMD of the lumbar spine in elderly men, but not in
women. In men also the relationship between both total
and free IGF-I and trochanter BMD reached borderline
significance.
These findings suggest that IGF-I levels do not play a
major role in protecting the elderly from bone loss with
aging. Serum free IGF-I is considered to be the major
biologically active hormonal form of IGF-I (7). However,
the assessment of serum free IGF-I levels in our study did
not give much more additional information than total
IGF-I, since the relationships between free IGF-I and
total IGF-I and BMD were almost identical.
Previous studies have shown an age-related decrease
in the serum level of total and free IGF-I (7, 12). Aging
is also characterized by a decrease in bone density and
a decrease in the IGF-I content of bone (13). Studies on
osteoporosis in men have shown a relationship between
low bone mass and lower serum IGF-I levels as a
consequence of decreased growth hormone secretion
(14, 15). Other observations suggest that changes in the
IGF-I content of bone may be related to changes in
serum IGF-I concentration (16), which raises the
possibility that the skeletal concentration of IGF-I
reflects deposition from serum IGF-I, rather than local
production (3). However, the relationship between
circulating (free and total) IGF-I levels and the lumbar
and trochanter BMD in men, as observed in our study,
contributes little to the issue of whether skeletal IGF-I
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Figure 1 Univariate relationships between (free and total) IGF-I and BMD of the lumbar spine respectively, in men and women.
Top: free IGF-I, bottom: total IGF-I. Left: men, right: women. The solid line represents the regression line. The dotted lines represent
the 95% confidence interval.
is predominantly derived from local production or from
the circulation. This is still a very complex issue as
circulating IGF-I is a marker of growth hormone activity
and may simply reflect the direct effects of growth
hormone on local skeletal IGF-I production. Moreover,
growth hormone and circulating IGF-I may have
indirect effects on bone mass, which may have nothing
to do with skeletal IGF-I production. For example, there
are many interactions between growth hormone/IGF-I
and estradiol in men and women and between calcium
and growth hormone. The issue is even more complex if
one considers that the interindividual differences in
skeletal IGF-I concentrations in old age may have
already existed when young, and correlations between
IGF-I and bone mass may be due to mixtures of genetic
and/or environmental influences (17). It is therefore
possible that any association between IGF-I and bone
mass in elderly individuals may be due to events which
occurred long before the actual measurements were
performed.
No relationships could be found between free and
total IGF-I and BMD in women. This relationship is
similar to that reported in postmenopausal women by
Kassem et al. (18), Bennett et al. (19) and Rosen et al.
(20). Although there are some studies which have
shown a positive relationship between BMD and IGF-I
in women (21, 22), the patients in the study of Pun et al.
(21) had also a concomitant vitamin D deficiency,
while in the study of Wuster et al. (22) both pre- and
postmenopausal women were included in the study. In
this latter study there was also a considerable difference
in age and body weight between patients and controls.
Finally, neither of these studies were population based.
The above mentioned associations between (free and
total) IGF-I and (lumbar and trochanter) BMD in men
turned out to be present only after adjustment for BMI.
It has previously been demonstrated that weight and
BMI are some of the strongest predictors of bone mass
at all ages in both sexes (23, 24), and this effect is
especially present at weight-bearing sites such as the
lumbar spine and the femur. We observed strong
associations between BMD and BMI in both sexes. In
men this result might be related to the contribution of
lean body mass to BMI, as it has been suggested that
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Figure 2 Univariate relationships between (free and total) IGF-I and BMD of the greater trochanter respectively, in men and women.
Top: free IGF-I, bottom: total IGF-I. Left: men, right: women. The solid line represents the regression line. The dotted lines represent the 95%
confidence interval.
lean body mass is the principal determinant of BMD
in men (25).
In conclusion, a weak positive relationship between
serum IGF-I and BMD was observed in men but not in
women, possibly indicating a gender-specific anabolic
effect of IGF-I on trabecular bone.
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